Asset profile
L-DOS47
Monoclonal antibody
Evidence outlook · lead readout
NCT02340208 · Non-Small Cell Lung Cancer
The reported results come from study designs that frequently fail to replicate under controlled conditions — see the rationale below.
NCT02340208: The study was open-label, non-randomized, and had no comparator arm; all 76 participants received dose-escalating L-DOS47. Its primary endpoint concerned treatment-related adverse events and tolerability, and results were not posted, so there is no reported primary comparison or evidence of benefit.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.